AlzeCure Pharma
AlzeCure Pharma is a Swedish biopharmaceutical company focused on developing small-molecule drug candidates for diseases of the central nervous system and pain. Its pipeline includes programs for Alzheimer’s disease, neuropathic pain, and other neurodegenerative or neurological indications, with development activities centered in Sweden.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueDrug candidates and research programs targeting Alzheimer’s disease and related cognitive disorders.
Programs focused on chronic and neuropathic pain, including TrkA-NAM and related assets.
Early-stage discovery work that generates new drug candidates and supporting scientific data.
Out-licensing and collaboration arrangements that monetize pipeline assets with partners.
Customers
AlzeCure does not sell mass-market products; its economic counterparties are primarily pharmaceutical and biotech partners, research collaborators, and potential licensees. In practice, value is created for larger drug developers that may acquire rights to its candidates, as well as public and private funding bodies that support clinical development.
Buy rights to drug candidates or programs for further development and commercialization.
Co-develop specific assets, share development risk, and support clinical advancement.
Provide non-dilutive funding for clinical studies and scientific work.
Support preclinical and translational research that strengthens the pipeline.
Strategy
The company’s strategy is to advance a focused pipeline of CNS and pain assets through preclinical and clinical milestones that can support licensing or collaboration deals. Scientific validation, patent protection, and external funding are central because they increase the attractiveness of the programs to larger pharmaceutical partners.
Progressing candidates increases partnering value and de-risks the pipeline.
The business model depends on external partners for downstream development and monetization.
Published data and patent protection improve negotiating leverage with larger pharma companies.
Geography
AlzeCure’s operations are centered in Sweden, where the parent company conducts its business and where the group structure is managed. The company’s commercial model is international in nature because licensing, clinical development, and eventual partnering can involve global pharmaceutical counterparties, even though the operating base remains Swedish.
Risks
AlzeCure’s main risks are typical of a development-stage biotech company: clinical failure, dependence on key personnel, and reliance on external financing or partnering to fund operations. Because future value is concentrated in milestone and royalty structures, delays or unsuccessful trial outcomes can materially reduce the economic value of its programs.
- Financing riskImpact: CriticalLikelihood: Medium
Development-stage biotech typically requires repeated external capital before product revenues exist.
Exposure: Ongoing R&D and clinical funding needs
- Clinical development riskImpact: HighLikelihood: Medium
Drug candidates may fail to show efficacy or safety in human studies, which can end a program.
Exposure - Partnering and milestone riskImpact: HighLikelihood: Low
A large share of potential value in licensing deals is tied to future milestones and royalties that may never be achieved.
Exposure: Future collaboration or license agreements
- Intellectual property riskImpact: HighLikelihood: Low
Patent expiry or weak protection can reduce partnering value and competitive exclusivity.
Exposure: Drug candidates and platform technologies
- Key-person riskImpact: MediumLikelihood: Medium
The company depends on specialized scientific, regulatory, and development expertise.
Exposure - Regulatory and trial approval riskImpact: MediumLikelihood: Medium
Clinical studies require regulatory permissions and compliance with trial standards.
Exposure: Human clinical programs in Sweden and abroad
Accounting
Judgemental itemsThe audit report notes uncertainty around sufficient working capital and dependence on new capital or licensing.
Impact: Affects valuation of the company as a continuing development business
Right-of-use assets and lease liabilities are recognized for office premises under IFRS 16.
Impact: Changes balance sheet leverage and operating expense presentation
EU and other research grants may be recognized based on compliance with grant conditions and project progress.
Impact: Can affect reported income timing and R&D expense offset
Future license deals may include upfront, milestone, and royalty components that require careful recognition judgments.
Impact: Could create uneven revenue timing and contingent income
Biotech companies must distinguish research from development activities under IFRS rules.
Impact: Affects operating expenses and intangible asset recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
BioArctic
BIOA-B · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Alpha Cognition Inc.
ACOG · Biological Products, (No Diagnostic Substances)
NeuroSense Therapeutics Ltd.
NRSNW · Pharmaceutical Preparations
Ascelia Pharma
ACE · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Alector, Inc.
ALEC · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026